Illumina Files Patent Suit Against Premaitha's Customer in Poland
January 08 2016 - 8:32AM
Dow Jones News
LONDON--Non-invasive prenatal test maker Premaitha Health PLC
(NIPT.LN) said Friday that Illumina, Inc. (ILMN) has filed a patent
infringement suit in Europe, against Premaitha's customer in
Poland.
Illumina has filed against Centrum Badań Sp z o.o. and
Medgenetix Sp z o.o. in the Regional Court in Warsaw, Poland.
The suit accuses Centrum and Medgenetix's use of the Iona
non-invasive prenatal testing or NIPT test supplied by Premaitha of
infringing European Patent 2 183 693.
Illumina has also taken similar action against Ariosa
Diagnostics, a subsidiary of Roche, and their customer, The Doctors
Laboratory, in the U.K..
Premaitha said it continues to make a robust defence against
earlier claims by Illumina and the board is confident that the IONA
test does not infringe the patents as claimed in the earlier cases
or in relation to Friday's announcement.
Premaitha's flagship product, the IONA test is a non-invasive in
vitro diagnostic product for prenatal screening enabling clinical
laboratories to offer CE-marked NIPT in-house for the first
time.
Shares at 1255 GMT down 2 pence, or 11%, at 16 pence.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
(END) Dow Jones Newswires
January 08, 2016 08:17 ET (13:17 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024